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Background: Kinins liberated from plasma–borne kininogens, are potent innate stimulatory signals. We evaluated
whether resistance to infection by Leishmania (L.) chagasi depends on activation of G-protein coupled bradykinin
B2 receptors (B2R).
Findings: B2R −/− C57BL/6 knock-out (KOB2) and B2R+/+ C57BL/6-wild type control mice (C57) were infected with
amastigotes of Leishmania (L.) chagasi. Thirty days after infection, the KOB2 mice showed 14% and 32% relative
increases of liver (p< 0.017) and spleen weights (p<0.050), respectively, whereas liver parasite load increased 65%
(p< 0.011) in relation to wild type mice. The relative weight increases of liver and spleen and the parasite load were
positively correlated (R = 0.6911; p< 0.007 to R = 0.7629; p< 0.001, respectively). Conversely, we found a negative
correlation between the increased liver relative weight and the weakened DTH response (a strong correlate to
protection or natural resistance to VL) or the decreased levels of IgG2b antibodies to leishmanial antigen. Finally,
we also found that IFN-γ secretion by splenocytes, an adaptive response that was significantly decreased in KOB2
mice (p< 0.002), was (i) negatively correlated to the increase in liver LDU (R = −0.6684; p = 0.035) and liver/body
relative weight (R = −0.6946; p = 0.026) and (ii) positively correlated to serum IgG2b levels (R = 0.8817; p = 0.001).
Conclusions: We found that mice lacking B2R display increased susceptibility to the infection by Leishmania (L.)
chagasi. Our findings suggest that activation of the bradykinin/B2R pathway contributes to development of host
resistance to visceral leishmaniasis.
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ResistanceFindings
VL is a chronic and vector-borne potentially fatal parasitic
disease caused by the Leishmania (L.) donovani / Leish-
mania (L.) infantum / Leishmania (L.) chagasi complex
which is associated to fever, malaise, anaemia, caquexia,
fatigue, enlargement of the liver, spleen and lymph nodes,
hypergammaglobulinemia and to the progressive suppres-
sion of cellular immunity [1,2]. Anti-parasite immune re-
sponse against the parasite is still present at early infection
and recovery after cure subsequent to chemotherapy; this* Correspondence: immgcpa@micro.ufrj.br
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reproduction in any medium, provided the orcan easily been assessed by the determination of the
delayed type hypersensitivity following injection of a leish-
manial antigen [3-5]. The variable degrees of susceptibility
or natural resistance to VL have been the focus of intense
studies in the mice and dog models [6,7] and in humans
[8] since the 70’s. A genetic basis for the susceptibility to
VL was described in mice, dogs and humans [7,9-11]. It is
well known that innate immunity plays a pivotal role in
host resistance to VL. There is now awareness that alert
signals expressed by pathogens and/or generated by
injured tissues might link the innate system to adaptive
immunity. Tissue injury can lead to bradykinin or Lysyl-
bradykinin excision from high and low molecular weight
kininogens by the respective action of the serine proteases,d. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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short-lived kinins induce inflammatory responses (e.g.
increased blood flow, oedema formation, vasodilatation
and pain sensation) through the activation of two distinct
subtypes of G-protein coupled bradykinin receptors (BR).
One of these, B2R, is constitutively expressed by a broad
range of host cell types, e.g., endothelial cells, epithelial
cells neurons and dendritic cells (DCs) [12,13]. In mice
infected subcutaneously by Trypanosoma cruzi, immature
CD11c+ DCs detect the presence of kinin peptides liber-
ated in peripheral sites of infection through the signalling
of B2R [14]. Upon maturation, the antigen-bearing B2R
+/+
DCs emigrate to secondary lymphoid tissues of chagasic
mice where they prime naive T cells while steering Th1
polarization via the IL-12-dependent pathway [13-15].
Using a systemic model of T.cruzi infection, Monteiro
et al. showed that B2R
−/− mice succumb to acute parasite
challenge [13]. After showing that B2R
−/− chagasic mice
failed to optimally develop type-1 T cell effectors, these
authors showed evidence that their susceptible phenotype
is a consequence of impaired maturation of splenic B2R
−/−
DCs [13]. Interestingly, in Balb/c infected (mucosally) with
the periodontal bacteria Porphyromonas gingivalis, the ac-
tivation of the kinin/B2R pathway generated IL-17 and
IFN-γ- producing T cells whereas infected C57BL/6 mice
exclusively generated IFN-γ-producing T cells, (likewise in
B2R-dependent manner) [16].
Regarding VL, in vivo studies in mice and hamsters
showed that Leishmania (L.) donovani and Leishmania
(L.) chagasi promastigotes evoke inflammatory oedema
through the proteolytic release of kinins [17]. In
addition, in vitro studies showed that activation of B2R
enhance parasite uptake by splenic adherent cells while
reducing amastigote outgrowth in inflammatory macro-
phages [17].
The Balb/c strain is extremely susceptible to tegu-
mentary leishmaniasis infections by L. (L.) mexicana, L.
(L.) major [18-21] and L. (L.) braziliensis [19] and the
C57BL/6 strain is resistant to the infection by L. (L.) major
[19-21] and L. (L.) braziliensis [19]. In the case of VL, on
the other hand, the C57BL/6 strain was considered equally
[18-20,22,23] or more susceptible [18] than the Balb/c
strain, to the infections by L.(L.) donovani, L.(L.) infantum
or L.(L.) chagasi, both developing high rates of parasites
loads in liver during early acute infection. Furthermore,
reflecting the genetic variability in the H2 locus, the Balb
H-2 d/d haplotype is associated with persisting visceral
leishmaniasis infection and the H-2b/b haplotype with sub-
stantial recovery by day 130 after infection [18]. However,
in spite of the impressive number of reports of VL studies
performed in the Balb/c model [5,19-22], all the transgenic
knock-out mice were developed within the C57BL/6 back-
ground and there are no B2R knock-out mice of Balb/c
genetic background.In this investigation we evaluated the potential role of the
bradykinin receptor B2R in resistance to VL using the
C57BL/6 wild type mice and its BR2 knock-out mutant




−/− knock-out (KOB2) [24] and C57BL/6-
B2R+/+ wild type control mice (C57) originated from
breeding colonies kindly donated by Dr J.B. Pesquero
(UNIFESP, São Paulo, Brazil) were maintained in our
animal facilities (LAT- IBCCF, UFRJ). Deletion of the en-
tire coding sequence of kinin B2 receptors was achieved
according to the methodology previously described by
Rupniak et al. [25]. Briefly, the generation of transgenic
B2R mice was achieved by transfection of embryonic
stem cells from J129 mice with a targeting vector
designed to disrupt the B2 receptor gene. Then hybrid
mice were obtained of the J129 and the C57 strain tak-
ing advantage the fertility capabilities of the C57 strain.
Once the hybrid is obtained it is possible to generate a
pure C57BL/6 B2R −/− strain through repeated back-
crossing with C57BL/6 [25]. All mouse studies followed
the guidelines set by the National Institutes of Health,
USA and the Institutional Animal Care and Use Com-
mittee approved the animal protocols (IBCCF, UFRJ,
protocol IMPPG-007).
Female C57BL/6 BR+/+ and B2R
−/− mice, 8-week-old,
were challenged intravenously with 3×107 L. (L.) chagasi
amastigotes obtained from infected hamsters spleens.
The strain used for challenge (IOC-L 3324) was origin-
ally isolated from the spleen of an infected dog
of Andradina, São Paulo, Brazil and taxonomically
characterized as Leishmania (L.) chagasi by the CLIOC-
WDCM 731 (Instituto Oswaldo Cruz Leishmania collec-
tion, Rio de Janeiro, Brazil). Thirty days after infection,
mice were euthanized using gaseous Carbon Dioxide
and the liver parasite load was evaluated in Giemsa-
stained smears and expressed in LDU values (Leishman
Donovan units of Stauber = number of amastigotes per
1000 liver cell nuclei/mg of liver weight) [6,18]. The
increases in liver and spleen/corporal relative weight
were also recorded as clinical signs of VL.
The DTH against L. (L.) donovani lysate was measured
in the footpads on day 28 after infection, as described
earlier [26]. Briefly, mice were injected intradermally, in
the right front footpad, with 107 freeze-thawed station-
ary phase Leishmania (L.) donovani (LD 1S/MHOM/SD/
00-strain 1S) promastigotes in 0.1 ml sterile saline solu-
tion. The contra-lateral footpad received 0.1 ml saline,
as control. Footpad thicknesses were measured with a
Mitutoyo apparatus, at 0, 24 and 48 h after injection. At
each measurement, the values of the saline control were









































Figure 1 Spleen and liver/body relative weights are increased in
B2R-deficient mice infected with L. (L.) chagasi. The body weight
was measured in grams at day 30 and the spleen (A) and liver / body
relative weights (grams of organ weight x 100 / grams of body
weight) (B) were determined in B2R
+/+ (C57) and B2R
−/− mice (KOB2).
Data represent the individual results for each group of mice (n = 3–5)
of three independent experiments. Asterisks indicate significant
differences between groups as disclosed by the Mann Whitney
analysis.
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CB hamsters demonstrated that the saline treated foot-
pads returned to base levels 24 h after inoculation [26].
Serum antibody responses were monitored by an
enzyme-linked immunosorbent assay (ELISA) using as
antigen the recombinant Nucleoside hydrolase (NH36)
of Leishmania (L.) donovani [27] or the freeze and
thawed lysate of stationary phase promastigotes of Leish-
mania (L.) chagasi (LIOC 579). The NH36 protein
cloned into the pET28b expression system was
expressed in E. coli Bl21DE3 cells and purified in a Ni-
NTA column (Qiagen) [27]. Thirty days after infection
with L. (L.) chagasi, sera were collected and the ELISA
assay performed by using 2 μg of recombinant NH36 or
promastigote lysate per well and goat anti-mouse IgG1
and IgG2b-horseradish peroxidase conjugate (Southern
Biotechnology Associates, Birmingham, Ala.) at 1:1,000
dilution in blocking buffer. The reaction was developed
with o-phenylenediamine (Sigma), interrupted with 1 N
sulphuric acid, and read at 492 ηm. Sera were analyzed
at a 1/100 dilution in triplicate. Positive and negative
control sera were included in each test.
Furthermore, for the assay of IFN-γ secretion we used
106 splenocytes after 5 days of in vitro culturing at 37°C
and 5% CO2 in RPMI medium [27] and/or 106 freeze-
thawed stationary phase Leishmania (L.) chagasi (IOC
L579) promastigotes in sterile saline solution obtained
from infected and uninfected C57 and BOK2 mice.
Secretions of IFN-γ were evaluated in the supernatants
with an enzyme-linked immunosorbent assay (ELISA)
using purified antimouse IFN-γ (clone R4–6A2; BD Bio-
science), biotin-conjugated antimouse IFN-γ (clone
XMG1.2; BD Bioscience), streptavidin-alkaline phosphat-
ase (BD Bioscience) and developed with ELISA Develop-
ment Kit from R&D System according to the
manufacturer’s instructions.
Statistical analysis
Means of variables were compared by Kruskall Wallis
and Mann Whitney non-parametrical tests (Analyze-it).
Correlation coefficient analysis was determined on a
Pearson bivariate, two tailed test of significance (SPSS
for windows). The values of R2 , which represents the
fraction of the total variance in Y that can be explained
by the variation in X, were obtained using linear regres-
sion analysis (Analyze-it).
Results
In order to evaluate whether kinins may contribute to im-
mune resistance to VL infection, wild type (C57) [22,23]
and B2R
−/− (KOB2) [13] mice were infected intravenously
with Leishmania (L.) chagasi amastigotes. All animals were
euthanized 30 days after infection in order to ascertain the
clinical parameters that characterize advanced VL, e.g., bymeasuring liver and spleen/body relative weight, both of
which are strong indicators of advanced VL [22,27]. Data
shown in Figure 1 disclosed that the spleen (p = 0.050)
(Figure 1A) and liver/body relative weight (Figure 1B) (p =
0.017) were significantly increased in KOB2-infected mice
as compared to the C57 mice. These results suggest that
B2R-receptor is implicated in the development of natural
host resistance to experimental VL.
Next, we measured DTH responses to the promastigote
leishmanial antigen to compare the efficiency of cellular
immunity in mice infected with Leishmania (L.) chagasi
[27]. Our data showed that the DTH response was signifi-
cantly lower in the KOB2 mice as compared to response
of the wild type infected animals (Figure 2A) (p = 0.003).

































Figure 2 Increased parasite tissue burden and impaired DTH
response in B2R deficient mice. (A) The y-axis represents the
individual results of the thickness of skin reaction in mm at 24 h
after intradermal injection of 107 freeze–thawed stationary phase
promastigotes, as measured on day 28 after infection in B2R
+/+ (C57)
and B2R
−/− mice (KOB2). The values of the contra-lateral saline
control were subtracted from the reaction due to Leishmania
antigen. Data represent the results of three independent
experiments performed with 3–5 mice for each treatment. (B) The y-
axis represents the average liver parasitic load in Leishman-Donovan
units of Stauber (LDU= number of amastigotes / 1000 cell nuclei ×
organ weight in mg) of two independent experiments (5 mice/
treatment), at 30 days after infection with 3 x 10 7 amastigotes of
Leishmania (L.) chagasi. T bars represent the SE values. Asterisks
indicate significant differences between groups as disclosed by the
Mann Whitney analysis.
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that activation of the kinin/B2R pathway is required for
optimal development of host resistance to LV. Consistent
with this, KOB2 mice displayed an increase in the relative
weight of spleen and liver (Figure 1 A and B), whereas the
DTH responses, as predicted, were impaired (Figure 2A).
Noteworthy, the parasite load was significantly increased
in the liver of the mutant mice (65%; p = 0.011; mean ±
SE = 2327.64 ± 795.41) over values of wild type mice
(818.73 ± 139.55) (Figure 2B).
Although we have not characterized the mechanisms
underlying the immune dysfunction of B2R
−/− mice
infected with Leishmania (L.) chagasi, studies in T. cruzi
infected B2R-deficient mice, which also exhibited asusceptible phenotype, revealed that host resistance to sys-
temic infection was impaired as a result of deficient DC
responsiveness to endogenously released kinins [13,15].
Our study showed that Leishmania (L.) chagasi infec-
tion of B2R
−/− mice accurately reproduced the advanced
VL clinical signs. For example, we found a highly signifi-
cant positive correlation between the spleen/body (R =
0.8600; p < 0.001), liver/ body relative weights (R =
0.6911; p < 0.007) and liver parasite load, all of which
were increased (Figure 3A). Likewise, the increases in
liver and spleen/body relative weights were also posi-
tively correlated (R = 0.7629; p < 0.001). Furthermore,
the decrease in DTH response against leishmanial anti-
gen was negatively correlated to the increase in liver/
body relative weight (R = −0.5003; p = 0.025)
(Figure 3B). Since DTH is a strong correlate of protec-
tion and required for optimal development of resistance
to VL [27-30], we may infer that the impaired DTH
observed in KOB2 mice is an expression of deficient cel-
lular immunity.
As an adjuvant to conclude on the immunological sta-
tus of the animals we also evaluated the anti-IgG1 and
IgG2b antibodies in mouse sera. Our ELISA assays
revealed that levels of IgG2b anti-NH36 antibodies in
the infected C57 mice were significantly higher (p =
0.018) as compared to the KOB2 mice (Figure 4). The
increase in IgG2b anti-NH36 antibodies and in DTH re-
sponse were positively correlated (R = 0.4587; p =
0.042). Furthermore, similar to the DTH response
(Figure 3B), the IgG2b increase was also negatively cor-
related to the increase in liver / body relative weight (R
= −0.5536; p = 0.011) (Figure 3C). When the ELISA
assay was performed, using as antigen the total L. (L.)
chagasi lysate, the levels of IgG1 and IgG2b antibodies
in the infected C57 mice were significantly higher (p =
0.008 and p= 0.032, respectively) as compared to the
KOB2 mice (Figure 4). The IgG1 or IgG2b antibodies
themselves, on the other hand, showed no significant
differences in their reactivity to NH36 or lysate, either
for C57 or BOK2 mice. Furthermore, the anti-lysate
IgG1 and IgG2b antibodies were positively correlated to
the IFN-γ secretion (R = 0.7063; p= 0.022 and R =
0.8735; p= 0.001, respectively) and negatively correlated
to the parasite load in liver (R = −0.6560; p= 0.039 and
R = −0.6963; p= 0.025, respectively). The anti-lysate
IgG2b antibodies were also negatively correlated to the
liver/ body relative weight (R = −0.6570; p= 0.039). Al-
though the anti-NH36 or anti-L.(L.) chagasi lysate IgG2b
antibodies are not protective by themselves, their
increased levels serve as an indicator of a TH1 response,
hence acting as a surrogate marker for natural resistance
to VL [31]. The definition of an antigen that would dis-
criminate antibodies generated during VL infection from
antibodies induced by vaccination or natural resistance
510





















































Figure 3 Correlation between the clinical signs of visceral leishmaniasis and the cellular versus antibody responses to leishmanial
antigen. Data represented in bivariate graphics: (A) the positive correlation between the individual increase of spleen and liver relative weights
and the increase in liver parasite load; and (B) the negative correlation between the increase in liver relative weight and the decrease in DTH
response to leishmanial antigen, and (C) the increase in liver relative weight and the decrease in anti-NH36 IgG2b antibody response. The results
were expressed on graphs as scattering of individual values. R-squared (R2) (coefficients of determination) estimates are shown on graphs. Trend
lines were added.









Figure 4 Evaluation of the IgG1 and IgG2b response in sera of
mice deficient of B2R. ELISA assay showing anti-Nucleoside
hydrolase (NH36) and anti-L.(L.) chagasi promastigote lysate IgG1
and IgG2b antibodies in B2R
+/+ wild type (C57) and B2R
−/− mice
(KOB2) intravenously infected with 3 x 107 amastigotes of
Leishmania. (L.) chagasi. Results are shown as the individual
absorbency values of 1/100 diluted sera obtained from two (NH36)
or one (lysate) experiment with 5 mice per treatment in each
experiment, at day 30 after infection. Asterisks indicate significant
differences between groups as disclosed by the Mann Whitney
analysis.
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the canine model of VL [30,32]. The complex promasti-
gote lysate or soluble antigen of L. (L.) infantum [33] or
L. (L.) chagasi [34] did not discriminate between infected
and vaccinated dogs. On the other hand Rafati et al.,
[33] showed that higher IgG2 than IgG1 titres were
detected against the recombinant antigens but not
against the L. (L.) infantum lysate. For these reasons, in
this investigation we compared the reactivity to the L.
(L.) chagasi promastigote lysate and to the NH36 Nu-
cleoside hydrolase protein, which is a phylogenetic con-
served marker of the Leishmania genus [35], a very
important enzyme in the DNA metabolism and estab-
lishment of the parasite infection [36] and an antigenic
marker of the canine patent disease [37]. Both antigens
discriminated between the C57 and KOB2 groups
regarding their IgG2b and only the lysate allowed detec-
tion differences in IgG1. The IgG2b antibodies are
expected to be increased in mice that show either vac-
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Figure 5 Assessment of the IFN-γ cytokine secretion by splenocytes. IFN-γ was assayed in the supernatants of splenocytes of C57 and KOB2
infected mice and in uninfected C57 and KOB2 control mice after 5 days of in vitro culture with the freeze and thawed lysate of Leishmania (L.)
chagasi promastigotes. Data correspond to individual results of one experiment with 6 mice of each group obtained after sacrifice. In graph A,
horizontal full lines represent the mean values of C57 normal uninfected (C57), C57 infected (C57i), KOB2 normal uninfected (KOB2) and KOB2
infected (KOB2i) mice. *p<0.05 indicates significant differences to the saline control as disclosed by the Kruskall Wallis (KW) and Mann Whitney
(MW) non-parametrical tests. The results were expressed on graphs as scattering of individual values. R squared (R2) (coefficients of determination)
estimates are shown on graphs. Trend lines were added.
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natants of splenocytes were significantly lower (p = 0.002)
in the KOB2 infected mice (mean = 0.74 ηg/ml) than in
the C57 infected mice (mean= 2.3 ηg/ml) (Figure 5). Both
groups were different from their respective uninfected
controls (p = 0.002 for each group) and neither the unin-
fected C57 or BOK2 mice secreted IFN-γ (p = 0.093). As
shown for the DTH and IgG2b response, the IFN-γ in
splenocyte supernatants was also a strong correlate for re-
sistance to VL since its secretion was negatively correlated
to the increase in liver LDU values (R = −0.6684; p=
0.035) and liver/ body relative weight (R = −0.6946; p=
0.026) and positively correlated to the IgG2b enhancement
(R = 0.8817; p = 0.001). In the C57 model of resistance to
VL therefore, the IFN-γ levels are also an indicator of a
TH1 response to Leishmania (L.) chagasi, which is dimin-
ished in mice lacking the B2 receptor for bradykinin.
It might be argued that the quantification of the para-
site load in bone marrow and spleen could also give a
view of the influence of the bradykinin B2-receptor.
Cotterell et al., [38] measured the parasite load in bone
marrow of Balb/c mice infected with 2 x 107 amastigotes
of L. (L.) donovani, through limiting dilution analysis ortissues smears and about 100 amastigotes were
recorded/1000 bone marrow cell nuclei at day 28 after
infection. The bone marrow parasite load was also stud-
ied by limiting dilution in Balb/c mice infected with L.
(L.) infantum by Carrión et al., [39]. Limiting dilution
differs from the direct microscopical counting of para-
sites in smears, in that the limiting dilution technique
involves the culture amplification of the true number of
parasites of the organ. In spite of this amplification, only
10 parasites were detected in bone marrow while
100,000 were detected in liver [39], showing that the
sensitivity for parasite detection in bone marrow is very
low, and any significant difference between the parasite
load of C57 and KOB2 mice in this organ are not
expected to be detected.
On the other hand, regarding the evaluation of the
spleen parasite load in our model, we observed a mean
average ± SD of 91.11 ± 29.13 LDU units for C57BL/6 +/+
mice and 70.43 ± 23.51 for C57BL/6 BR2 −/− mice, with
no significant differences between the two groups. Similar
levels (75 LDUs) were reported by Cotterell et al., [38] in
Balb/c mice and much lower values were described by Ato
et al., [23], who worked with C57BL/6 mice infected with
Nico et al. Parasites & Vectors 2012, 5:261 Page 7 of 8
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donovani) and obtained an average of only 2 LDU at 14
days, and 10 LDU at 28 days after infection. This is prob-
ably due to the fact that in the classical model of mice VL
acute infection after endovenous injection of the parasites,
used by most authors [18,22,23,38,40], reviewed in [41] an
early acute infection is detected in the liver and a later
chronic infection in spleen, each one characterized by its
own organ-specific immune responses [23,40]. We con-
clude that, in our model of acute VL infection, the best lo-
cation to investigate the parasite load at day 30 after
infection was the liver, where high parasite loads and sig-
nificant differences between the C57BL/6 BR2−/− and the
C57BL/6 BR2+/+ wild type controls were found. Therefore,
the liver gives the best view of the role of the BR2 receptor
in resistance to VL at this earlier point of infection.
Conclusions
In summary, our results suggest that the natural resist-
ance to the development of VL in C57BL/6 mice is at
least partially dependent of the presence and functional-
ity of the kinin/B2R receptor pathway.
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